JPMorgan analyst Jessica Fye raised the firm’s price target on BioNTech (BNTX) to $121 from $116 and keeps a Neutral rating on the shares. The firm updated the company’s model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- CDC panel votes against requiring prescriptions for Covid shots, Bloomberg says
- Pfizer, BioNTech express dedication to making safe Covid vaccines
- CDC panel votes to end universal Covid vaccine recommendation, Bloomberg says
- Trump Trade: Trump expected to extend deadline for TikTok sale
- Pfizer (PFE), Moderna (MRNA) Stocks Slide on Report Linking Child Deaths to COVID Vaccines